Listed

Mettler Toledo International Inc/: Form 10-Q for the period ended Sep 30, 2018

Filed with the SEC on Nov 9, 2018 and accepted by EDGAR at Nov 9, 2018, 10:15 ET.

Share

Management's discussion and analysis

As filed, 32,717 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Unaudited Interim Consolidated Financial Statements included herein.

General

Our interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the full year ending December 31, 2018.

Changes in local currency exclude the effect of currency exchange rate fluctuations. Local currency amounts are determined by translating current and previous year consolidated financial information at an index utilizing historical currency exchange rates. We believe local currency information provides a helpful assessment of business performance and a useful measure of results between periods. We do not, nor do we suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. We present non-GAAP financial measures in reporting our financial results to provide investors with an additional analytical tool to evaluate our operating results.

We also include in the discussion below disclosures of immaterial qualitative factors that are not quantified. Although the impact of such factors is not considered material, we believe these disclosures can be useful in evaluating our operating results.

Results of Operations – Consolidated

The following tables set forth certain items from our interim consolidated statements of operations for the three and nine month periods ended September 30, 2018 and 2017 (amounts in thousands).

Three months ended September 30, 2018 (unaudited)% 2017 (unaudited)% Nine months ended September 30, 2018 (unaudited)% 2017 (unaudited)%
Net sales $734,846 100.0 $698,799 100.0 $2,117,663 100.0 $1,947,022 100.0
Cost of sales 315,592 42.9 297,824 42.6 910,851 43.0 827,046 42.5
Gross profit 419,254 57.1 400,975 57.4 1,206,812 57.0 1,119,976 57.5
Research and development 34,838 4.7 32,203 4.6 104,866 5.0 95,985 4.9
Selling, general and administrative 202,451 27.6 207,033 29.6 611,149 28.9 588,313 30.2
Amortization 11,856 1.6 10,716 1.5 35,561 1.7 31,010 1.6
Interest expense 9,003 1.2 8,248 1.2 25,671 1.2 24,160 1.2
Restructuring charges 2,222 0.3 3,385 0.5 13,956 0.6 8,840 0.5
Other charges (income), net (1,479) (0.1) (237) — (5,795) (0.3) (8,654) (0.4)
Earnings before taxes 160,363 21.8 139,627 20.0 421,404 19.9 380,322 19.5
Provision for taxes 33,710 4.6 34,677 5.0 89,979 4.2 81,326 4.1
Net earnings $126,653 17.2 $104,950 15.0 $331,425 15.7 $298,996 15.4

Net sales

Net sales were $734.8 million and $698.8 million for the three months ended September 30, 2018, and 2017, and $2.1 billion and $1.9 billion for the nine months ended September 30, 2018 and September 30, 2017, respectively. This represents an increase of 5% and 9% in U.S. dollars for the three and nine months ended September 30, 2018. Excluding the effect of currency exchange rates fluctuations, or in local currencies, net sales increased 7% and 6% for the three and nine months ended September 30, 2018. The Biotix acquisition contributed approximately 1% to local currency net sales for the three and nine months ended September 30, 2018. These results compare to 6% and 9% local currency growth for the three and nine months ended September 30, 2017 of which acquisitions contributed approximately 1%. Global market conditions were generally favorable during the first nine months of 2018 and we continue to benefit from the execution of our global sales and marketing programs, our innovative product portfolio, and investments in our field resources. However, we remain cautious as market conditions are subject to change and economic uncertainties exist in certain regions of the world.

Net sales by geographic destination for the three and nine months ended September 30, 2018 in U.S. dollars increased in the Americas by 5% in both periods, in Europe 1% and 9%, and in Asia/Rest of World 9% and 14%, respectively. Our net sales by geographic destination for the three and nine months ended September 30, 2018 in local currencies increased in the Americas by 5% in both periods, in Europe by 3% in both periods, and in Asia/Rest of World by 11% and 10%, respectively. The Biotix acquisition contributed approximately 1% and 2% to our local currency net sales growth in the Americas for the three and nine months ended September 30, 2018. A discussion of sales by operating segment is included below.

As described in Note 17 to our consolidated financial statements for the year ended December 31, 2017, our net sales comprise product sales of precision instruments and related services. Service revenues are primarily derived from repair and other services, including regulatory compliance qualification, calibration, certification, preventative maintenance and spare parts.

Net sales of products increased 6% in U.S. dollars and 7% in local currencies for the three months ended September 30, 2018 and increased 9% in U.S. dollars and 6% in local currencies for the nine months ended September 30, 2018, compared to the corresponding periods in 2017. The Biotix acquisition contributed approximately 1.5% to our net sales of products for both the three and nine months ended September 30, 2018. Service revenue (including spare parts) increased by 3% in U.S. dollars and 4% in local currencies for the three months ended September 30, 2018 and increased 8% in U.S. dollars and 5% in local currencies for the nine months ended September 30, 2018, compared to the corresponding periods in 2017.

Net sales of our laboratory products and services, which represented approximately 51% of our total net sales increased 9% in U.S. dollars and 11% in local currencies for the three months ended September 30, 2018, and increased 13% in U.S. dollars and 10% in local currencies for the nine months ended September 30, 2018. The local currency increase in net sales of our laboratory products includes strong growth in most product categories, especially process analytics, automated chemistry and pipettes. The Biotix acquisition also contributed approximately 2% to our growth of laboratory products and services for both the three and nine months ended September 30, 2018.

Net sales of our industrial products and services, which represented approximately 41% of our total net sales decreased 1% in U.S. dollars and increased 1% in local currencies for the three months ended September 30, 2018, and increased 4% in U.S. dollars and 1% in local currencies for the nine months ended September 30, 2018. The local currency increase in net sales of our industrial products includes growth in core-industrial, offset in part by a decline in product inspection.

Net sales in our food retailing products and services, which represented approximately 8% of our total net sales increased 12% in U.S. dollars and 14% in local currencies for the three months ended September 30, 2018, and increased 10% in U.S. dollars and 6% in local currencies for the nine months ended September 30, 2018. Food retailing experienced strong growth in each region during the three month period with particularly strong project activity in the Americas for both the three and nine month periods. Net sales in Europe declined during the nine month period against strong growth in the prior year.

Gross profit

Gross profit as a percentage of net sales was 57.1% and 57.4% for the three months ended September 30, 2018 and 2017, and 57.0% and 57.5% for the nine months ended September 30, 2018 and 2017, respectively.

Gross profit as a percentage of net sales for products was 59.6% and 60.2% for the three months ended September 30, 2018 and 2017, respectively, and 60.2% and 61.0% for the nine months ended September 30, 2018 and 2017, respectively.

Gross profit as a percentage of net sales for services (including spare parts) was 47.8% and 47.3% for the three months ended September 30, 2018 and 2017, respectively, and 45.8% and 45.5% for the nine months ended September 30, 2018 and 2017, respectively.

The decrease in gross profit as a percentage of net sales for the three and nine months ended September 30, 2018 was primarily due to initial costs associated with a new manufacturing facility and product introductions, the Biotix acquisition, unfavorable business mix and tariff costs, offset in part by favorable price realization.

In 2018, the U.S. government enacted tariffs on certain products imported from China. The tariffs became effective at various points during 2018. We estimate the associated annualized cost increase is approximately $25 million (assuming a 25% tariff rate). We are evaluating and implementing various actions to mitigate the effect of the tariffs.

Research and development and selling, general and administrative expenses

Research and development expenses as a percentage of net sales was 4.7% and 4.6% for the three months ended September 30, 2018 and 2017, and was 5.0% and 4.9% for the nine months ended September 30, 2018 and 2017, respectively. Research and development expenses increased 9% in U.S. dollars and increased 10% in local currencies for the three months ended September 30, 2018, and increased 10% in U.S. dollars and increased 7% in local currencies for the nine months ended September 30, 2018, respectively, compared to the corresponding periods in 2017 relating to increased project activity.

Selling, general and administrative expenses as a percentage of net sales were 27.6% and 29.6% for the three months ended September 30, 2018 and 2017, and was 28.9% and 30.2% for the nine months ended September 30, 2018 and 2017, respectively. Selling, general and administrative expenses decreased 2% in U.S. dollars and 1% in local currencies for the three months ended September 30, 2018, and increased 4% in U.S. dollars and 1% in local currencies for the nine months ended September 30, 2018. The local currency increase includes investments in our field sales organization and growth initiatives, offset in part by benefits from our cost savings initiatives. The decrease for the three and nine months ended September 30, 2018 also includes lower cash incentive expense.

Amortization, interest expense, other charges (income), net and taxes

Amortization expense was $11.9 million and $10.7 million for the three months ended September 30, 2018 and 2017, respectively, and $35.6 million and $31.0 million for the nine months ended September 30, 2018 and 2017, respectively.

Interest expense was $9.0 million and $8.2 million for the three months ended September 30, 2018 and 2017, respectively, and $25.7 million and $24.2 million for the nine months ended September 30, 2018 and 2017, respectively.

Other charges (income), net includes non-service pension costs (benefits), (gains) losses from foreign currency transactions and related hedging activities, interest income and other items. Nonservice pension benefits were $1.6 million and $1.2 million for the three months ended September 30, 2018 and 2017, respectively, and $4.7 million and $3.1 million and for the nine months ended September 30, 2018 and 2017, respectively. Other charges (income), net for the nine months ended September 30, 2017 also includes a one-time gain of $3.4 million relating to the sale of a facility in Switzerland in connection with our initiative to consolidate certain Swiss operations into a new facility.

Our reported tax rate was 21% and 25% during the three months ended September 30, 2018 and 2017, respectively and 21% during both the nine months ended September 30, 2018 and 2017, respectively. The provision for taxes is based upon using our projected annual effective tax rate of 21.5% before non-recurring discrete tax items for the three and nine month periods ended September 30, 2018. The difference between our projected annual effective tax rate of 21.5% and our reported tax rate is related to the timing of excess tax benefits associated with stock option exercises. The three month period ended September 30, 2018 also includes a cumulative year-to-date benefit of $1.3 million from reducing our annual projected effective tax rate from 22.0% to 21.5% related to the first six months of 2018.

On December 22, 2017, the Tax Cuts and Jobs Act (the "Act") significantly revised U.S.corporate income tax law. The Act includes, among other things, a reduction in the U.S. federal corporate income tax rate from 35% to 21% effective for taxable years beginning after December 31, 2017, and the implementation of a modified territorial tax system that includes a one-time transition tax on deemed repatriated earnings of foreign subsidiaries ("Transition Tax") that is payable over a period of up to eight years.

Our accounting for the Act is based upon reasonable estimates, however, our estimates may

change upon the finalization of the Act's implementation and additional interpretive guidance from

regulatory authorities. Among other things, we need to complete our analysis of historical foreign

earnings and related taxes paid and our analysis of foreign cash equivalents. In addition, we need to

complete our analysis of deemed repatriation of deferred foreign income and related state tax effects. We will complete our accounting for the above tax effects of the Act during the fourth quarter of 2018 as provided in SAB 118 and will reflect any adjustments to our provisional amounts at that time. We estimate any such adjustments will not be material to our financial statements.

Results of Operations – by Operating Segment

The following is a discussion of the financial results of our operating segments. We currently have five reportable segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations and Other. A more detailed description of these segments is outlined in Note 17 to our consolidated financial statements for the year ended December 31, 2017.

U.S. Operations (amounts in thousands)

Three months ended September 30, Nine months ended September 30,
2018 2017% 2018 2017%
Total net sales $280,429 $263,408 6% $808,801 $763,097 6%
Net sales to external customers $255,379 $239,221 7% $736,598 $693,405 6%
Segment profit $41,890 $43,004 (3)% $118,141 $126,973 (7)%

Total net sales and net sales to external customers both increased 6% for the three and nine months ended September 30, 2018 compared with the corresponding period in 2017. Net sales to external customers benefited approximately 3% from the Biotix acquisition for the three and nine month periods ended September 30, 2018. The increase in total net sales and net sales to external customers for the three and nine months ended September 30, 2018 reflects strong results in our laboratory products, as well as strong food retailing project activity. These results were offset in part by a decrease in product inspection which had strong growth in the prior year periods.

Segment profit decreased $1.1 million and $8.8 million for the three and nine months ended September 30, 2018, respectively, compared to the corresponding periods in 2017, primarily due to initial costs associated with a new manufacturing facility and new product introductions and continued investments in our field sales and service organization, offset in part by benefits from our margin expansion initiatives.

Swiss Operations (amounts in thousands)

Three months ended September 30, 2018 2017 %1) Nine months ended September 30, 2018 2017 %1)
Total net sales $179,881 $170,883 5% $537,041 $491,816 9%
Net sales to external customers $31,463 $33,923 (7)% $96,082 $95,957 —%
Segment profit $44,542 $39,212 14% $138,254 $113,181 22%

1) Represents U.S. dollar growth (decline) for net sales and segment profit.

Total net sales increased 5% in U.S. dollars and 8% in local currency for the three months ended September 30, 2018, and increased 9% in U.S. dollars and 8% in local currency for the nine months ended September 30, 2018 compared to the corresponding periods in 2017. Net sales to external customers decreased 7% in U.S. dollars and 6% in local currency for the three months ended September 30, 2018 and were flat in U.S. dollars and decreased 1% in local currency for the nine months ended September 30, 2018, compared to the corresponding periods in 2017. The decline in local currency net sales to external customers for the three and nine months ended September 30, 2018 includes decreases in industrial-related products and food retailing.

Segment profit increased $5.3 million and $25.1 million for the three and nine month periods ended September 30, 2018, compared to the corresponding periods in 2017. Segment profit during the three and nine months ended September 30, 2018 includes the impact of increased inter-segment sales volume, our margin expansion initiatives and favorable foreign currency translation, offset in part by higher research and development activity.

Western European Operations (amounts in thousands)

Three months ended September 30, 2018 2017 %1) Nine months ended September 30, 2018 2017 %1)
Total net sales $215,093 $212,009 1% $640,390 $597,318 7%
Net sales to external customers $173,170 $171,722 1% $512,314 $470,206 9%
Segment profit $30,046 $32,519 (8)% $75,661 $81,946 (8)%

1) Represents U.S. dollar growth (decline) for net sales and segment profit.

Total net sales increased 1% in U.S. dollars and 3% in local currencies for the three months ended September 30, 2018 and increased 7% in U.S. dollars and 1% in local currencies for the nine months ended September 30, 2018, compared to the corresponding periods in 2017. Net sales to external customers increased 1% in U.S. dollars and increased 2% in local currencies for the three months ended September 30, 2018, and increased 9% in U.S. dollars and 2% in local currencies for the nine months ended September 30, 2018, compared to the corresponding periods in 2017. Local currency net sales to external customers for the nine months ended September 30, 2018 includes growth in most product categories, offset in part by a decline in food retailing which had strong project activity in the prior nine month period ended September 30, 2017.

Segment profit decreased $2.5 million and $6.3 million for the three and nine month periods ended September 30, 2018, respectively, compared to the corresponding periods in 2017. The decrease in segment profit for the three and nine month period ended September 30, 2018 includes higher research and development activity, an inter-segment product transfer and roll-in costs associated with our Blue Ocean program, offset by benefits from our margin expansion initiatives and favorable currency translation.

Chinese Operations (amounts in thousands)

Three months ended September 30, 2018 2017 %1) Nine months ended September 30, 2018 2017 %1)
Total net sales $204,177 $193,692 5% $570,375 $502,533 14%
Net sales to external customers $140,098 $125,067 12% $387,301 $323,940 20%
Segment profit $75,762 $69,086 10% $201,199 $167,873 20%

1) Represents U.S. dollar growth for net sales and segment profit.

Total net sales increased 5% in U.S. dollars and 7% in local currency for the three months ended September 30, 2018 and increased 14% in U.S. dollars and 9% local currency for the nine months ended September 30, 2018, compared to the corresponding periods in 2017. Net sales to external customers increased 12% in U.S. dollars and 14% in local currency for the three months ended September 30, 2018 and increased 20% in U.S. dollars and 15% local currency during the nine months ended September 30, 2018, compared to the corresponding periods in 2017. The increase in local currency net sales to external customers during the three and nine months ended September 30, 2018 reflects very strong growth in most product categories, especially laboratory products. While Chinese market conditions are currently favorable, there is uncertainty, including the potential impact of international trade disputes. The Chinese economy has historically been volatile and market conditions may change unfavorably due to various factors.

Segment profit increased $6.7 million and $33.3 million for the three and nine month periods ended September 30, 2018, respectively, compared to the corresponding periods in 2017. The increase in segment profit for the three and nine months ended September 30, 2018 includes increased local currency net sales volume, benefits from our margin expansion and cost savings initiatives, and favorable foreign currency translation.

Other (amounts in thousands)

Three months ended September 30, 2018 2017 %1) Nine months ended September 30, 2018 2017 %1)
Total net sales $136,070 $130,620 4% $389,804 $368,995 6%
Net sales to external customers $134,736 $128,866 5% $385,368 $363,514 6%
Segment profit $19,179 $16,754 14% $50,702 $45,043 13%

1) Represents U.S. dollar growth for net sales and segment profit.

Total net sales increased 4% in U.S. dollars and 7% in local currencies for the three months ended September 30, 2018 and increased 6% in U.S. dollars and 3% in local currencies for the nine months ended September 30, 2018, compared to the corresponding periods in 2017. Net sales to external customers increased 5% in U.S. dollars and 7% in local currencies for the three months ended September 30, 2018 and increased 6% in U.S. dollars and 4% in local currencies for the nine months ended September 30, 2018, compared to the corresponding periods in 2017. Local currency sales growth for the three month period reflects strong growth in laboratory and core-industrial products.

Segment profit increased $2.4 million and $5.7 million for the three and nine months ended September 30, 2018, respectively, compared to the corresponding periods in 2017.The increase in segment profit is primarily due to our increased sales volume, benefits from our margin expansion initiatives and favorable foreign currency translation, offset in part by increased sales and service investments.

Liquidity and Capital Resources

Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In addition, liquidity includes the ability to obtain appropriate financing. Currently, our financing requirements are primarily driven by working capital requirements, capital expenditures, share repurchases and acquisitions.

Cash provided by operating activities totaled $366.4 million during the nine months ended September 30, 2018, compared to $351.2 million in the corresponding period in 2017. The increase in 2018 is primarily related to higher net income, offset in part by higher cash incentive payments, the timing of tax payments and a Transition Tax payment of $4.2 million (see below).

Capital expenditures are made primarily for investments in information systems and technology, machinery, equipment and the purchase and expansion of facilities. Our capital expenditures totaled $96.7 million for the nine months ended September 30, 2018 compared to $85.8 million in the corresponding period in 2017. The increase is primarily related to investments in manufacturing facilities, and information technology. We expect to make net investments in new or expanded manufacturing facilities of approximately $20 million over the next two years.

In 2017, we recorded a provisional one-time charge of $72 million for the estimated income tax effect of the Transition Tax associated with the Tax Cuts and Jobs Act of which $59 million is expected to be paid over a period of up to eight years. In April 2018, we paid our first Transition Tax payment of $4.2 million.

We plan to repatriate earnings from China, Switzerland, Germany, the United Kingdom and certain other countries in future years and expect the only additional cost associated with the repatriation of such earnings outside the United States will be any applicable withholding taxes. All other undistributed earnings are considered to be permanently reinvested. As of September 30, 2018, we have an immaterial amount of cash and cash equivalents outside the United States where undistributed earnings are considered permanently reinvested. Accordingly, we believe the tax impact associated with repatriating our undistributed foreign earnings will not have a material effect on our liquidity.

Senior Notes and Credit Facility Agreement

Our debt consisted of the following at September 30, 2018:

September 30, 2018 U.S. Dollar Other Principal Trading Currencies Total
3.67% $50 million Senior Notes due December 17, 2022 50,000 — 50,000
4.10% $50 million Senior Notes due September 19, 2023 50,000 — 50,000
3.84% $125 million Senior Notes due September 19, 2024 125,000 — 125,000
4.24% $125 million Senior Notes due June 25, 2025 125,000 — 125,000
1.47% EUR 125 million Senior Notes due June 17, 2030 — 146,938 146,938
Debt issuance costs, net (950) (335) (1,285)
Total Senior Notes 349,050 146,603 495,653
$1.1 billion Credit Agreement, interest at LIBOR plus 87.5 basis points 443,776 49,465 493,241
Other local arrangements 14 55,739 55,753
Total debt 792,840 251,807 1,044,647
Less: current portion (14) (55,739) (55,753)
Total long-term debt $792,826 $196,068 $988,894
  • 31 -

On June 15, 2018 we entered into an amended $1.1 billion Credit Agreement (the "Credit Agreement"), which amended our $800 million Amended and Restated Credit Agreement (the "Prior Credit Agreement"), that is further described in Note 7 of our consolidated financial statements.

As of September 30, 2018, approximately $601 million was available under the Credit Agreement. Changes in exchange rates between the currencies in which we generate cash flows and the currencies in which our borrowings are denominated affect our liquidity. In addition, because we borrow in a variety of currencies, our debt balances fluctuate due to changes in exchange rates.

In April 2018, two of our non-U.S. pension plans issued loans totaling $39.6 million (Swiss franc 38 million) to our wholly owned subsidiary. The loans have the same terms and conditions which include an interest rate of Swiss franc LIBOR plus 87.5 basis points and a maturity date of April 2019 and a one year renewal term and, as such, are classified as short-term debt on our consolidated balance sheet. The proceeds were used to repay outstanding amounts on our credit facility.

We currently believe that cash flow from operating activities, together with liquidity available under our credit facility and local working capital facilities, will be sufficient to fund currently anticipated working capital needs and capital spending requirements for at least the foreseeable future.

We continue to explore potential acquisitions. In connection with any acquisition, we may incur additional indebtedness.

Share Repurchase Program

As of September 30, 2018, we had $227.2 million of remaining availability under the Company's share repurchase program. On November 8, 2018, the Company's Board of Directors authorized an additional $2.0 billion to the share repurchase program. The share repurchases are expected to be funded from cash generated from operating activities, borrowings, and existing cash balances. Repurchases will be made through open market transactions, and the amount and timing of purchases will depend on business and market conditions, stock price, trading restrictions, the level of acquisition activity, and other factors.

We have purchased 27.3 million shares since the inception of the program through September 30, 2018. During the nine months ended September 30, 2018 and 2017, we spent $356.2 million and $335.0 million on the repurchase of 598,539 and 647,756 shares at an average price per share of $595.18 and $517.15, respectively. We also reissued 102,174 shares and 206,646 shares held in treasury for the exercise of stock options and restricted stock units during the nine months ended September 30, 2018 and 2017, respectively.

Effect of Currency on Results of Operations

Our earnings are affected by changing exchange rates. We are most sensitive to changes in the exchange rates between the Swiss franc, euro, and U.S. dollar. We have more Swiss franc expenses than we do Swiss franc sales because we develop and manufacture products in Switzerland that we sell globally, and have a number of corporate functions located in Switzerland. When the Swiss franc strengthens against our other trading currencies, particularly the U.S. dollar and euro, our earnings go down. We also have significantly more sales in the euro than we do expenses. When the euro weakens against the U.S. dollar and Swiss franc, our earnings also go down. We estimate a 1% strengthening of the Swiss franc against the euro would reduce our earnings before tax by approximately $1.6 million to $1.8 million annually.

We also conduct business in many geographies throughout the world, including Asia Pacific, the United Kingdom, Eastern Europe, Latin America, and Canada. Fluctuations in these currency exchange rates against the U.S. dollar can also affect our operating results. The most significant of these currency exposures is the Chinese Renminbi. The impact on our earnings before tax of the Chinese Renminbi weakening 1% against the U.S. dollar is a reduction of approximately $1.2 million to $1.4 million annually.

In addition to the effects of exchange rate movements on operating profits, our debt levels can fluctuate due to changes in exchange rates, particularly between the U.S. dollar and the Swiss franc. Based on our outstanding debt at September 30, 2018, we estimate that a 10% weakening of the U.S. dollar against the currencies in which our debt is denominated would result in an increase of approximately $28.0 million in the reported U.S. dollar value of our debt.

Forward-Looking Statements Disclaimer

You should not rely on forward-looking statements to predict our actual results. Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties. You can identify forward-looking statements by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue”.

We make forward-looking statements about future events or our future financial performance, including earnings and sales growth, earnings per share, strategic plans and contingency plans, growth opportunities or economic downturns, our ability to respond to changes in market conditions, planned research and development efforts and product introductions, adequacy of facilities, access to and the costs of raw materials, shipping and supplier costs, gross margins, customer demand, our competitive position , capital expenditures, cash flow, tax-related matters, compliance with laws, and effects of acquisitions.

Our forward-looking statements may not be accurate or complete, and we do not intend to update or revise them in light of actual results. New risks also periodically arise. Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements. See in particular “Factors Affecting Our Future Operating Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2017 Annual Report on Form 10-K.

Market risk

As filed, 178 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As of September 30, 2018, there was no material change in the information provided under Item 7A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Controls and procedures

As filed, 708 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer, have concluded that these disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting during the quarter ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 204 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

For the nine months ended September 30, 2018 there were no material changes from risk factors disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-07-01 to 2018-09-30$734.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2018-01-01 to 2018-09-30$2.12bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Gross profit3 months2018-07-01 to 2018-09-30$419.3mus-gaap:GrossProfit
Gross profit9 months2018-01-01 to 2018-09-30$1.21bnus-gaap:GrossProfit
Research and development3 months2018-07-01 to 2018-09-30$34.8mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2018-01-01 to 2018-09-30$104.9mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2018-07-01 to 2018-09-30$202.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2018-01-01 to 2018-09-30$611.1mus-gaap:SellingGeneralAndAdministrativeExpense
Interest expense3 months2018-07-01 to 2018-09-30$9.0mus-gaap:InterestExpense
Interest expense9 months2018-01-01 to 2018-09-30$25.7mus-gaap:InterestExpense
Income tax3 months2018-07-01 to 2018-09-30$33.7mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2018-01-01 to 2018-09-30$90.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-07-01 to 2018-09-30$126.7mus-gaap:NetIncomeLoss
Net income9 months2018-01-01 to 2018-09-30$331.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-07-01 to 2018-09-30$4.93us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2018-01-01 to 2018-09-30$12.81us-gaap:EarningsPerShareDiluted
Basic EPS3 months2018-07-01 to 2018-09-30$5.04us-gaap:EarningsPerShareBasic
Basic EPS9 months2018-01-01 to 2018-09-30$13.10us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2018-07-01 to 2018-09-3025,683,365 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2018-01-01 to 2018-09-3025,877,979 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2018-01-01 to 2018-09-30$366.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2018-01-01 to 2018-09-30$96.7mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2018-01-01 to 2018-09-30$356.2mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2018-09-30$137.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-09-30$971.5mus-gaap:AssetsCurrent
Total assetsAt period end2018-09-30$2.56bnus-gaap:Assets
Current liabilitiesAt period end2018-09-30$697.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-09-30$2.03bnus-gaap:Liabilities
Long-term debtAt period end2018-09-30$988.9mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2018-09-30$55.8mus-gaap:DebtCurrent
Shareholders' equityAt period end2018-09-30$531.6mus-gaap:StockholdersEquity
Shares outstandingAt period end2018-09-3025,045,028 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001037646-18-000030. Last ingested by Listed: Nov 13, 2026, 02:43 ET. Listed shows no prices and gives no investment advice.